HER-2 Positive Breast Cancer Terminated Phase 2 Trials for Eribulin (DB08871)

IndicationStatusPhase
DBCOND0042425 (HER-2 Positive Breast Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01912963Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast CancerTreatment